Skip to main content

Advertisement

Table 2 Current chemotherapy regimensa

From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy

  APF530
250 mg
APF530
500 mg
Palonosetron
0.25 mg
MEC regimens, n (%) n = 149 n = 140 n = 134
 Docetaxel-trastuzumab 0 1 (0.7) 2 (1.5)
 Doxorubicin 1 (0.7) 1 (0.7) 1 (0.7)
 Cyclophosphamide-anthracycline 121 (81.2) 108 (77.1) 102 (76.1)
 Cyclophosphamide-docetaxel 7 (4.7) 7 (5.0) 13 (9.7)
 5-FU-cyclophosphamide-methotrexate 10 (6.7) 11 (7.9) 5 (3.7)
 Docetaxel-epirubicin 4 (2.7) 3 (2.1) 3 (2.2)
HEC regimens, n (%) n = 60 n = 67 n = 58
 Cyclophosphamide-doxorubicin 2 (3.3) 3 (4.5) 0
 5-FU-cyclophosphamide-anthracycline 29 (48.3) 33 (49.3) 33 (56.9)
 Cyclophosphamide-docetaxel-doxorubicin 15 (25.0) 10 (14.9) 7 (12.1)
 Carboplatin-docetaxel-trastuzumab 5 (8.3) 5 (7.5) 5 (8.6)
 Carboplatin-docetaxel 2 (3.3) 5 (7.5) 4 (6.9)
 Carboplatin-paclitaxel 0 4 (6.0) 2 (3.4)
 Carboplatin-gemcitabine 1 (1.7) 2 (3.0) 1 (1.7)
  1. aReceived by 3 or more patients
  2. 5-FU 5-fluorouracil; HEC highly emetogenic chemotherapy; MEC moderately emetogenic chemotherapy